SLNO: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-22,468	-48,481
Depreciation and amortization	1,508	1,006
Accretion of premium/discount on marketable securities	2,325	1,954
Non-cash lease expense	484	364
Amortization of debt issuance costs	26	17
Accrued clinical trial site costs	-	37
Stock-based compensation expense	34,375	24,377
Change in fair value of contingent consideration	4,682	4,068
Other non-cash reconciling items	-30	-16
Accounts receivable	25,506	24,624
Inventory	6,011	2,095
Prepaid expenses, other current assets and other assets	1,287	339
Accounts payable	-674	-2,603
Accrued compensation	2,472	1,491
Operating lease liabilities	-189	-74
Other liabilities	12,977	3,434
Net cash used in operating activities	-1,906	-45,360
Purchases of property and equipment	15	14
Purchases of marketable securities	267,936	104,764
Maturities of marketable securities	191,530	119,800
Net cash used in investing activities	-76,421	15,022
Proceeds from the sale of common stock, net of issuance costs	215,721	-
Payment of debt issuance costs	62	62
Proceeds from exercise of common stock warrants	5,187	5,187
Proceeds from exercise of stock options	16,248	13,993
Payment of deferred financing costs	-	178
Tax withholding payments for net share-settled equity awards	33	33
Net cash provided by financing activities	237,061	18,907
Net increase (decrease) in cash and cash equivalents	158,734	-11,431
Cash and cash equivalents at beginning of period	87,928	-
Cash and cash equivalents at end of period	246,662	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

SLNO: the cashflow